Timed Sequential Salvage Chemotherapy for Relapsed or Refractory Acute Myeloid Leukemia

Abstract

Therapy for those with relapsed or refractory acute myeloid leukemia is suboptimal. Studies have suggested that timed sequential salvage combination cytotoxic chemotherapy may be particularly useful for that indication. We report here a series of ten such adult patients treated sequentially at a single center with EMA (cytarabine 500 mg/m2/day as continuous infusion on days 1–3 and days 8–10, mitoxantrone 12 mg/m2/day on days 1–3, and etoposide 200 mg/m2/day as continuous infusion on days 8–10). The overall complete remission rate was 40% (including 3 of 4 of those with relapsed disease), but use of this regimen was associated with prolonged cytopenia and a high rate of infectious adverse events. Even with the availability of modern infectious prophylaxis and therapies, the EMA regimen is likely best reserved for those with relapsed disease treated with curative intent prior to an allogeneic hematopoietic cell transplant.

Keywords

• Acute myeloid leukemia
• Timed sequential chemotherapy
• EMA
• Chemotherapy
• Refractory AML
• Relapsed AML